Loading...
XNASIART
Market cap1.68bUSD
Jan 10, Last price  
21.81USD
1D
-1.98%
1Q
13.42%
Jan 2017
-49.16%
Name

Integra Lifesciences Holdings Corp

Chart & Performance

D1W1MN
XNAS:IART chart
P/E
24.84
P/S
1.09
EPS
0.88
Div Yield, %
0.00%
Shrs. gr., 5y
-0.99%
Rev. gr., 5y
0.92%
Revenues
1.54b
-1.03%
229,825,000277,935,000419,297,000550,459,000654,604,000682,487,000732,068,000780,078,000830,871,000836,214,000928,305,000882,734,000992,075,0001,188,236,0001,472,441,0001,517,557,0001,371,868,0001,542,448,0001,557,666,0001,541,573,000
Net income
68m
-62.48%
17,197,00037,194,00029,407,00033,471,00034,933,00050,955,00065,669,00027,989,00041,204,000-16,977,00034,004,000-3,519,00074,564,00064,743,00060,801,00050,201,000133,892,000169,075,000180,550,00067,741,000
CFO
140m
-47.08%
38,975,00056,848,00071,702,00047,026,00072,590,000143,235,000105,571,000104,328,00058,715,00053,268,00079,463,00094,483,000116,405,000114,544,000199,683,000373,682,000203,832,000312,427,000264,469,000139,955,000
Earnings
Feb 26, 2025

Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
IPO date
Aug 16, 1995
Employees
3,722
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,541,573
-1.03%
1,557,666
0.99%
Cost of revenue
827,772
688,548
Unusual Expense (Income)
NOPBT
713,801
869,118
NOPBT Margin
46.30%
55.80%
Operating Taxes
13,328
33,344
Tax Rate
1.87%
3.84%
NOPAT
700,473
835,774
Net income
67,741
-62.48%
180,550
6.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
(275,000)
(144,153)
BB yield
7.86%
3.08%
Debt
Debt current
29,815
52,749
Long-term debt
1,834,000
1,734,654
Deferred revenue
7,700
8,800
Other long-term liabilities
192,240
129,701
Net debt
1,524,009
763,401
Cash flow
Cash from operating activities
139,955
264,469
CAPEX
(66,865)
(47,085)
Cash from investing activities
(94,178)
(58,580)
Cash from financing activities
(229,925)
(251,953)
FCF
628,581
695,776
Balance
Cash
309,096
456,661
Long term investments
30,710
567,341
Excess cash
262,727
946,119
Stockholders' equity
932,662
890,288
Invested Capital
3,206,779
2,667,975
ROIC
23.85%
29.42%
ROCE
20.37%
24.00%
EV
Common stock shares outstanding
80,337
83,516
Price
43.55
-22.33%
56.07
-16.30%
Market cap
3,498,676
-25.29%
4,682,742
-18.23%
EV
5,022,685
5,446,143
EBITDA
837,313
987,417
EV/EBITDA
6.00
5.52
Interest
51,377
49,594
Interest/NOPBT
7.20%
5.71%